03/06/2026
𧬠EASL Recommendations: HCV Treatment in Transplant Recipients
π― General Principles
All HCV-infected transplant recipients should be treated with DAAs
Aim: SVR (cure) β improves graft and patient survival οΏ½
Interferon is contraindicated (risk of rejection)
Use interferon-free DAA regimens only
β± Timing of Therapy
π« Liver Transplant
Before transplant:
If feasible β reduces post-trans recurrence
After transplant:
Treat all patients with recurrent HCV infection
π§ Other Solid Organs (Kidney, Heart, Lung)
Treat after transplant once stable
π Recommended Regimens (EASL 2020 Final Update)
β
Pangenotypic First-line Options
Sofosbuvir + Velpatasvir (SOF/VEL)
12 weeks
All genotypes
Safe in most transplant recipients
Glecaprevir + Pibrentasvir (GLE/PIB)
12 weeks (preferred in transplant)
All genotypes
Sofosbuvir + Velpatasvir + Voxilaprevir
12 weeks
For DAA-experienced / failure cases
π These regimens achieve SVR >95% even post-transplant οΏ½
π« Organ-Specific Recommendations
π§ 1. Liver Transplant Recipients
Indication: Recurrent HCV infection (universal if viremic)
Regimens:
SOF/VEL (12 weeks)
GLE/PIB (12 weeks)
β οΈ Decompensated graft cirrhosis:
Avoid protease inhibitors (GLE/PIB, VOX)
Use:
SOF/VEL Β± Ribavirin
π§ 2. Kidney Transplant Recipients
If eGFR β₯30 ml/min:
Any DAA (including sofosbuvir-based)
If eGFR 95%
Improved:
Graft survival
Liver function
Overall mortality οΏ½